STAT Plus: Biogen delays Alzheimer’s drug filing to FDA, citing Covid-19, complexity of data analysis
DOMINICK REUTER/AFP/GETTY IMAGES
The company's comments raise speculation that FDA might be pushing back on the controversial findings, but executives say they remain confident in the data.
.png)
No hay comentarios:
Publicar un comentario